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Summary  Esthesioneuroblastomas  (ENB)  are  rare  tumours  derived  from  the  olfactory  epithe-
lium. Based  on  their  experience  and  a  review  of  the  literature,  the  authors  tried  to  identify
the epidemiological,  clinical,  histological  and  therapeutic  factors  that  inﬂuence  overall  and
disease-free  survival  in  their  series  of  ENB.
Methods:  This  retrospective  study  concerned  eleven  patients  treated  in  a  single  institution  for
ENB of  the  nasal  cavity  and  sinuses  between  1978  and  2006.  The  data  collected  were  submitted
to statistical  analysis  using  R  2.0® software.  Overall  survival  and  disease-free  survival  were
estimated  by  the  Kaplan-Meier  method  and  prognostic  factors  were  identiﬁed  by  Log-Rank
test.
Results: This  series  comprised  three  women  (27.2%)  and  eight  men  (72.8%)  (sex  ratio:  2.6).  The
mean age  at  diagnosis  was  56  years  (range:  37—69  years).  No  risk  factors  were  identiﬁed  in  this
cohort. The  mean  follow-up  was  110.2  months  (range:  7—348  months).  This  series  included  three
T1 (27.3%),  one  T2  (9.1%),  four  T3  (36.3%)  and  three  T4  (27.3%)  tumours.  The  1-year,  5-year  and
10-year disease-free  survival  rates  were  81.8%,  54.5%  and  18.2%,  and  the  corresponding  overall
survival  rates  were  100%,  90%  and  60%,  respectively.  The  main  prognostic  factors  reported  in
the literature  are  tumour  stage  at  diagnosis,  adjuvant  radiotherapy  and  radiation  dose.
Conclusion:  ENB  are  characterized  by  a  high  recurrence  rate  and  recurrences  can  occur  a  very
long time  after  the  diagnosis,  indicating  the  need  for  prolonged  follow-up  of  these  patients.
The 5-year  and  10-year  overall  survival  rates  are  about  90%  and  60%,  respectively.
.  All  
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ntroductionsthesioneuroblastoma  (ENB)  was  ﬁrst  described  in  1924.
hese  rare  tumours  are  derived  from  olfactory  epithelium
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nd  usually  arise  in  the  olfactory  cleft  [1,2]. Most  pub-
ished  series  concern  retrospective  studies  based  on  small
ample  sizes.  However,  several  international  multicentre
tudies  have  been  published,  based  on  a  greater  num-
er  of  cases,  allowing  identiﬁcation  of  prognostic  factors
3].  In  a  meta-analysis  of  all  published  cases  from  1924
ntil  1997,  Broich  et  al.  reported  a  total  of  945  cases
2].
served.
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Table  1  Dulguerov’s  TNM  classiﬁcation.
Dulguerov’s  classiﬁcation  [1992]
T1:  tumour  involving  the  nasal  cavity  excluding  the
sphenoid  sinus
T2:  tumour  involving  the  nasal  cavity  including  the
sphenoid  sinus
T3:  tumour  extending  to  the  orbit  or  anterior  cranial  fossa
T4: tumour  involving  the  brain
N0:  no  cervical  lymph  node  metastases
N1:  cervical  lymph  node  metastases
M0: no  metastases
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apy  (cisplatin/5-ﬂuorouracil):  18.2%  (n  =  2);  neoadjuvantM1:  distant  metastases
Based  on  our  experience  and  a  review  of  the  literature,
we  tried  to  identify  epidemiological,  clinical,  histologi-
cal  and  therapeutic  factors  inﬂuencing  overall  survival  and
disease-free  survival  in  our  series  of  ENB.
Patients and methods
This  retrospective  study  was  based  on  11  patients  managed
in  our  institution  for  ENB  of  the  nasal  cavity  and  sinuses
between  1978  and  2006.
Epidemiological  data,  clinical  and  imaging  ﬁndings,  his-
tology,  treatment  modalities  and  outcome  of  patients  were
studied.  To  ensure  a  homogeneous  series,  Dulguerov’s  TNM
classiﬁcation,  presented  in  Table  1,  was  applied  to  all
patients  either  retrospectively  (patients  managed  before
1992)  or  prospectively  (patients  managed  after  1992)  [4].
The  database  was  created  with  FileMaker  Pro® software
(version  5;  Microsoft  Corp.  Ltd,  Redmond,  USA).  Statisti-
cal  analysis  of  overall  survival  and  disease-free  survival  was
performed  according  to  the  Kaplan-Meier  method.  The  prog-
nostic  value  of  the  following  elements  on  overall  survival
and  disease-free  survival  was  investigated  by  univariate
analysis  (Log-Rank  test):  age,  gender,  T  status,  tumour
extension  (involvement  of  key  structures  such  as  the  sphe-
noid  sinus,  frontal  sinus,  orbit,  eyeball,  anterior  cranial
fossa,  cavernous  sinus,  brain),  histological  grade,  surgical
management  and  adjuvant  radiotherapy.  For  all  tests,  a  P
value  less  than  0.05  was  considered  statistically  signiﬁcant.
All  statistical  analyses  were  performed  with  R  2.0® software.
Results
Epidemiological  data
This  series  comprised  three  women  (27.2%)  and  eight  men
(72.8%),  i.e.  a  sex  ratio  of  2.6.  The  mean  age  at  diagno-
sis  was  56  years  (range:  37—69  years).  The  tumour  was
located  on  the  right  side  in  four  cases  (36.4%),  the  left  side
in  three  cases  (27.2%)  and  the  lesion  was  bilateral  in  four
cases  (36.4%).  No  occupational  exposure  risk  factor  (leather
tannin,  wood  dust,  exposure  to  nickel)  was  identiﬁed.  The
median  follow-up  was  102  months  (range:  7—348  months).
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linical  features
nitial  symptoms  were  unilateral  in  90.9%  of  cases.  The  most
ommon  symptoms  were  nasal  obstruction  (70%)  and  epis-
axis  (30%).  Other  presenting  complaints  were  pain  (20%),
iplopia  or  exophthalmos  (20%),  neurological  signs  (20%)  and
kin  signs  (10%).
ite,  extension  and  TNM  classiﬁcation
he  initial  assessment  in  all  patients  managed  after  1991
n  =  10)  comprised  contrast-enhanced  CT  scan  of  the  facial
ones  for  local  staging  and  contrast-enhanced  CT  of  the  neck
nd  chest  for  regional  and  distant  staging.  This  assessment
as  completed  by  MRI  of  the  facial  bones  in  eight  patients
80%).  Review  of  imaging  allowed  assessment  of  tumour
ites,  modes  of  extension  and  staging.  The  initial  assess-
ent  for  the  patient  diagnosed  in  1976  was  not  available
or  review.
In  every  case,  the  tumours  arose  from  the  olfactory  cleft.
he  lesion  was  strictly  conﬁned  to  one  nasal  cavity  in  two
ases  (18.2%),  and  extended  to  the  sphenoid  sinus  in  one
ase  (9.1%),  the  frontal  sinus  in  one  case  (9.1%),  the  orbit
n  two  cases  (18.2%),  the  eyeball  in  one  case  (9.1%),  the
nterior  cranial  fossa  in  three  cases  (27.3%),  the  cavernous
inus  in  one  case  (9.1%)  and  the  brain  in  three  cases  (27.3%).
This  series  comprised  three  stage  T1  (27.3%),  one  stage
2  (9.1%),  four  stage  T3  (36.3%)  and  three  stage  T4  (27.3%)
umours.  One  patient  (9.1%)  had  positive  lymph  nodes  at
iagnosis  and  was  staged  as  T4N2c  (retropharyngeal,  spinal
nd  bilateral  jugulo-carotid  lymphadenopathy).  No  patients
ad  metastatic  disease  at  diagnosis.
The  patient  with  a  high-grade  malignant  tumour  with
ymph  node  invasion  at  the  initial  diagnosis  was  alive  with
isease  at  the  time  of  data  collection,  i.e.  68  months  after
he  diagnosis.
istological  data
he  histological  grade  was  determined  for  only  eight  (63.6%)
f  the  11  cases  of  histologically  documented  ENB:  grade
 in  one  case  (12.5%),  grade  II  in  two  cases  (25%),  grade
II  in  three  cases  (37.5%)  and  grade  IV  in  two  cases  (25%).
he  immunohistochemical  proﬁle  of  the  tumour  was  deter-
ined  in  six6  cases.  At  least  one  neuroendocrine  marker  was
resent  in  all  cases  (Neuron-Speciﬁc  Enolase  [NSE],  Chromo-
ranin  or  synaptophysin).  PS  100  was  positive  in  four  cases
nd  negative  in  two  cases.  Epithelial  markers  were  negative
n  ﬁve  cases  and  positive  in  one  case.
reatment  modalities
he  initial  treatment  consisted  of  four  different  modalities:
urgery  alone:  27.3%  (n  =  3);  surgery  followed  by  adjuvant
adiotherapy:  36.3%  (n  =  4);  concurrent  chemoradiother-hemotherapy  (cisplatin/etoposide  and  cisplatin/5-
uorouracil)  (18.2%)  followed  by  chemoradiotherapy  in  one
ase  and  surgery  in  one  case,  both  staged  as  T4N0M0.
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Table  2  Esthesioneuroblastoma  — local  recurrence,  regional  recurrence  and  distant  recurrence  as  a  function  of  TNM  status  and
initial treatment  modalities.
T  status  Initial  treatment  Total  number  of  patients  Local  recurrence  Regional  recurrence  Distant  recurrence
T1  Surgery  +  RT  1  1  0  0
Surgery alone  2  1  0  1
T2 Surgery  +  RT  1  0  0  0
T3 Surgery  +  RT  1  0  0  0
CRT 1  0  0  0
T4 Surgery alone  1  1  0  0
Surgery +  RT 1 0 1 0
CT  +  Surgery 1 1 0 0
CT  +  CRT 1  0  1a 0
CRT 1  1a 0  0
Surgery + RT: surgery followed by radiotherapy; Surgery alone: surgery alone; CRT: concurrent chemoradiotherapy; CT + Surgery:
ed by concurrent chemoradiotherapy.
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Discussion
This  study  shows  that  ENB  are  rare  tumours  that  can  be
associated  with  very  long  survival.  The  age,  sex  ratio  and
lateralisation  of  the  tumours  in  this  series  are  identical  to
those  reported  in  the  literature  [5—7]. No  male  or  female
predominance  has  been  reported  [1,8]. These  tumours  usu-
ally  present  during  the  sixth  and  seventh  decades,  but  cases
Table  3  Results  of  univariate  analyses  of  the  prognostic
impact  of  the  variables  studied  in  our  series  on  overall  sur-
vival and  disease-free  survival.
Variable  tested  Impact  on
overall  survival
Impact  on
disease-free
survival
Age  Not  signiﬁcant
(P  =  0.874)
Not  signiﬁcant
(P  =  0.31)
Gender  Not  signiﬁcant
(P  =  0.403)
Not  signiﬁcant
(P  =  0.754)
Dulguerov  T  status
T1  vs  T2  vs  T3  vs  T4
Not  signiﬁcant
(P  =  0.786)
Not  signiﬁcant
(P  =  0.255)
Dulguerov  T  status
T1T2  vs  T3T4
Not  signiﬁcant
(P  =  0.874)
Not  signiﬁcant
(P  =  0.369)
Tumour  extension
(sphenoid,  frontal
sinus,  orbit,
eyeball,  anterior
cranial  fossa,
cavernous  sinus,
brain)
Not  signiﬁcant
(P  =  0.874)
Not  signiﬁcant
(P  =  0.369)
Histological  grade  Not  signiﬁcant
(P  =  0.754)
Not  signiﬁcant
(P  =  0.31)
Surgery  vs  other
treatment
modalities
Not  signiﬁcant
(P  =  0.874)
Not  signiﬁcant
(P  =  0.525)chemotherapy followed by surgery; CT + CRT: chemotherapy follow
a Patients with progressive disease on completion of initial trea
Overall,  eight  patients  (72.2%)  were  operated,  ﬁve  via
 craniofacial  incision  (one  T1,  three  T3  and  one  T4),  two
y  degloving  (one  T1  and  one  T2)  and  one  by  endonasal
urgery  (T1).  Macroscopically  negative  surgical  margins  were
btained  in  all  operated  patients.  Surgical  margins  were
egative  on  histological  examination  in  seven  of  these  eight
ases.  The  pathologist  was  unable  to  provide  this  informa-
ion  for  one  case  due  to  fragmentation  of  the  operative
pecimen.
Radiotherapy  was  delivered  according  to  a  nonfractio-
ated  protocol  at  doses  ranging  between  45  and  70  Gy  to
he  tumour  bed.  The  patient  with  T4N2c  disease  received  a
ose  of  56  Gy  to  the  tumour  bed  and  lymph  node  areas.
Actuarial  1-year,  5-year  and  10-year  disease-free  survival
ates  were  81.8%,  54.5%  and  18.2%  and  actuarial  1-year,  5-
ear  and  10-year  overall  survival  rates  were  100%,  90%  and
0%,  respectively.
Eight  treatment  failures  (72.7%)  were  observed.  Two
atients,  one  T4N0  and  one  T4N2c,  (18.2%  of  all  patients)
resented  progressive  disease  on  completion  of  initial  treat-
ent  and  another  six  patients  relapsed  and  were  staged  as
1  in  three  cases  and  T4  in  three  cases.  Results  for  local  and
istant  recurrence  are  presented  in  Table  2,  according  to
ite,  TNM,  and  treatment  modalities.  The  mean  recurrence-
ree  survival  was  53  months  (range:  16—115  months).
Patients  who  developed  recurrence  were  treated  by  redo
urgery  in  three  cases,  chemoradiotherapy  (cisplatin/5-
uorouracil)  in  one  case,  chemotherapy  alone  in  one  case
nd  radiotherapy  alone  in  one  case.  Salvage  therapy  for
ate  recurrence  (9  and  11  years)  was  effective  in  two  cases.
hese  two  patients  were  in  complete  remission  at  the  time
f  data  collection  (with  a  follow-up  of  2  years  and  21  years,
espectively).  Treatment  of  local  recurrence  was  surgical  in
oth  cases.
Three  patients  died  from  progression  of  their  disease  (one
1  and  two  T4)  and  three  patients  were  alive  with  disease
t  the  time  of  data  collection.
Univariate  analyses  failed  to  demonstrate  any  prognos-
ic  impact  on  overall  survival  and  disease-free  survival  for
ny  of  the  variables  tested,  especially  tumour  extension
Table  3).
Adjuvant
radiotherapy  versus
surgery  alone
Not  signiﬁcant
(P  =  0.256)
Not  signiﬁcant
(P  =  0.31)
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Table  4  Five-year  and  10-year  disease-free  survival  (DFS)  and  overall  survival  (OS)  of  esthesioneuroblastoma  indicating  the
percentage of  patients  treated  by  surgery  and  adjuvant  radiotherapy.
Authors Patients(n)  5-year  DFS
(%)
10-year  DFS
(%)
5-year  OS(%)  10-year  OS
(%)
Adjuvant  RT  rate
(%)
Beitler  et  al.  [6]  14  57  41  86  70  100
Dulguerov  et  al.  [8]  390  41  52  45  —  —
Diaz et  al.  [5]  30  69  38  89  81  77
Jethanamest  et  al.  [1] 311  —  —  62.1  45.6  —
Bachar et  al.  [7] 39 76  44.7  87.2  69.2  76
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have  also  been  reported  in  children  and  in  elderly  subjects
over  the  age  of  80  years  [1,2]. The  absence  of  prognostic
signiﬁcance  of  these  factors  on  survival,  as  observed  in  this
study  and  as  reported  in  the  literature,  is  probably  due  to
the  very  small  sample  sizes  of  published  series.  Similarly,  no
risk  factor  for  the  pathogenesis  of  these  tumours  has  ever
been  identiﬁed  [8].
The  initial  clinical  symptoms  of  tumours  of  the  facial
bones,  including  ENB,  are  often  nonspeciﬁc  [9].  The  symp-
toms  most  commonly  reported  in  the  literature  are  identical
to  those  described  in  our  study  [2,8].
The  main  prognostic  factor  for  overall  survival  and
disease-free  survival  reported  in  the  literature  is  clinical
stage  at  the  time  of  diagnosis  [1,4,7]. ENB  staging  can
be  evaluated  according  to  two  classiﬁcations:  the  Kadish
classiﬁcation  modiﬁed  by  Morita  and  the  Dulguerov  TNM
classiﬁcation  [4,10]. Based  on  a  cohort  of  311  patients,
Jethanamest  et  al.  showed  that  10-year  overall  survival
and  disease-free  survival  (Kaplan-Meier  analysis)  were  83.4%
and  90%,  respectively,  for  patients  with  a  tumour  con-
ﬁned  to  the  nasal  cavity  (modiﬁed  Kadish  Type  A),  49%  and
68.3%  for  patients  with  a  tumour  involving  the  paranasal
sinuses  (modiﬁed  Kadish  Type  B),  36%  and  66.7%  for  patients
with  a  tumour  extending  beyond  the  paranasal  sinuses
(modiﬁed  Kadish  Type  C)  and  13.3%  and  35.6%  for  patients
with  metastatic  disease  (modiﬁed  Kadish  Type  D)  (P  <  0.01)
[1,11].  These  results  are  similar  to  those  reported  in  the
meta-analysis  by  Broich  et  al.  [2]  and  similar  results  have
also  been  published  for  T  status  of  Dulguerov’s  TNM  classiﬁ-
cation.  In  a  series  of  39  patients,  Bachar  et  al.  demonstrated
a  statistically  signiﬁcant  survival  difference  according  to  T
stage  with  5-year  and  10-year  overall  survivals  of  100%  for
T1,  100%  and  89%  for  T2,  89%  and  53%  for  T3  and  56%  and
28%  for  T4.  Disease-free  survival  was  also  signiﬁcantly  inﬂu-
enced  by  Dulguerov’s  T  status  in  Bachar’s  series  [7].  Like
Bachar  et  al.,  we  also  used  Dulguerov’s  classiﬁcation,  which
appears  to  be  the  most  appropriate  classiﬁcation  [7],  as  it
reliably  reﬂects  the  course  of  these  tumours  by  allowing  a
good  description  of  local  tumour  extension.
The  results  of  the  present  series  are  compared  to  those
of  the  literature  in  Table  4  [1,5—8]. All  studies  conﬁrm  the
possibility  of  late  recurrence  many  years  after  the  initial
diagnosis  [4,5].
The positive  lymph  node  rate  at  the  time  of  diagnosis
varies  according  to  the  studies  between  5  and  10%  [1,12],
with  a  similar  rate  in  the  present  series.  Jugular  lymph  nodes
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re  most  commonly  involved,  but  retropharyngeal  lymph
ode  involvement,  as  observed  in  the  patient  with  T4N2c
isease,  is  not  exceptional  in  ENB  [13]. In  2008,  Zollinger
t  al.  reported  four  cases  of  metastatic  disease  in  this  ter-
itory  in  a  series  of  17  patients  managed  for  ENB  [14].
atients  with  lymph  node  metastases  at  the  time  of  diag-
osis  require  multimodal  management,  comprising  surgery
nd  radiotherapy,  as  soon  as  possible  [13]. There  are  no
rguments  in  the  literature  in  favour  of  the  use  of  surgery
lone  or  radiotherapy  alone  [13]. No  consensus  has  been
eached  concerning  the  optimal  management  of  patients
ith  clinical  and  radiological  N0  disease.  However,  as  the
requency  of  recurrence  at  this  site  ranges  from  15  to  30%  in
he  literature  [8,12,15],  most  authors  agree  that  prophylac-
ic  treatment  of  cervical  lymph  nodes  must  be  considered  in
he  presence  of  a  locally  advanced  tumour.  [8,12,15].  The
evelopment  of  late  metachronous  lymph  node  metastases
more  than  6  months  after  the  initial  diagnosis)  is  not  rare.
ore  et  al.,  in  a meta-analysis  based  on  678  patients,
eported  late  metachronous  lymph  node  metastases  in  12.8%
f  cases  [16]. These  lymph  node  metastases  also  require
ultimodal  treatment  at  least  including  surgery,  whenever
ossible,  and  radiotherapy  [13,16].  The  presence  of  lymph
ode  metastases  has  been  reported  to  be  a  factor  of  poor
rognosis  [8,17]. Distant  metastases  are  rare  and  are  also
ssociated  with  a  very  poor  prognosis  [8].
Well-differentiated  ENB  is  a  simple  diagnosis.  Immuno-
istochemistry  is  a  very  valuable  tool  in  less  well-
ifferentiated  forms.  Three  differential  diagnoses  must  be
onsidered:  neuroendocrine  carcinoma,  mucosal  melanoma
nd  sinonasal  undifferentiated  carcinoma  (SNUC)  [18,19].
Discordant  results  have  been  published  concerning  the
rognostic  value  of  histological  grade  [19]. In  several  stud-
es,  Hyams’  classiﬁcation  appeared  to  have  a  signiﬁcant
rognostic  value:  56%  survival  in  grade  I-II  (low-grade)  and
5%  survival  in  grade  III-IV  (high-grade)  [2,8,20],  but  this
ssociation  was  not  conﬁrmed  in  the  present  series.
Several  studies  have  compared  the  respective  results
f  surgery  alone,  radiotherapy  alone,  the  combination
f  surgery  and  radiotherapy  and  the  contribution  of
hemotherapy  [1,5,21].  Surgery  followed  by  adjuvant  radio-
herapy  appears  to  be  superior  to  radiotherapy  or  surgery
lone  [5].  Based  on  a  series  of  274  patients,  Jethanamest
t  al.  conﬁrmed  that  the  mean  survival  of  patients  treated
y  a  combination  of  surgery  and  radiotherapy  was  216.8
onths  (range:  188—245)  versus  208  months  for  surgery
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lone  and  92.8  months  for  radiotherapy  alone  (P  <  0.002
adiotherapy  versus  combined  therapy)  [1].  Similar  results
ere  published  by  Foote  et  al.  in  1993  [11]. Although  these
urvival  differences  were  not  observed  in  the  present  series,
robably  because  of  the  small  sample  size,  management  of
hese  tumours  in  our  centre  now  systematically  comprises
djuvant  radiotherapy.  The  multicentre  study  conducted  by
zsahin  et  al.  in  77  patients  demonstrated  the  prognostic
alue  of  negative  surgical  margins  [3].
Several  authors  have  reported  the  possibility  of  com-
lete  endoscopic  resection  of  tumours  conﬁned  to  the  nasal
avity  and  paranasal  sinuses.  A  neurosurgical  approach,  pos-
ibly  combined  with  a  transfacial  approach,  is  recommended
y  most  authors  for  the  treatment  of  lesions  extending  to
he  skull  base  [22—25]. The  place  of  endoscopic  surgery  in
he  treatment  of  ENB  was  the  subject  of  a  meta-analysis
ased  on  361  patients  operated  between  1992  (date  of  the
rst  known  publications  on  endoscopic  surgery)  and  2008
26]. The  authors  found  better  survival  rates  (overall  and
isease-free  survival)  after  endoscopic  surgery  than  after
pen  surgery.  However,  these  results  are  inﬂuenced  by  the
act  that  open  surgery  is  mainly  performed  for  Kadish  stage
 and  D  disease.  The  authors  concluded  that  endoscopic
urgery  is  possible  but  must  be  reserved  to  less  advanced
umours  [26]. The  number  of  studies  comparing  these  two
ypes  of  surgery  for  advanced  tumours  is  insufﬁcient  at  the
resent  time  [26].
Radiation  doses  have  also  been  reported  to  be  a  prog-
ostic  factor  in  some  studies.  Ozsahin  et  al.  showed  that  a
inimum  dose  of  54  Gy  to  the  tumour  bed  provides  a  good
hance  of  survival  [3].  We  did  not  demonstrate  any  impact
f  adjuvant  radiotherapy  on  the  survival  of  our  patients,
robably  because  of  the  small  sample  size.
The  value  of  chemotherapy  has  been  poorly  evalu-
ted  on  the  basis  of  small  series  [27]. Chemotherapy  can
e  proposed  either  in  the  adjuvant  setting  for  curable
esions  in  combination  with  radiotherapy,  or  for  unre-
ectable  advanced  or  metastatic  tumours.  The  molecules
ost  commonly  used  are  cisplatin  and  etoposide  or  dox-
rubicin  or  vincristine  [28]. Neoadjuvant  chemotherapy
induction  chemotherapy)  for  advanced  tumours,  using
isplatin  and  5-ﬂuorouracil  or  etoposide,  doxorubicin  or
incristine,  has  also  been  reported  in  the  literature  [28].
ost  teams  using  chemotherapy  also  delivered  sequential
r  concurrent  radiotherapy  [28]. Encouraging  results  have
een  obtained,  indicating  that  the  treatment  of  ENB  must
e  multimodal.  Hyams’  classiﬁcation  appears  to  be  predic-
ive  of  the  response  to  chemotherapy  [27]. Only  patients
ith  very  advanced  disease  were  treated  by  chemotherapy
n  the  present  series.
Only  two  of  the  six  patients  with  local  or  regional  failure
esponded  to  salvage  therapy.  Salvage  therapy  appears  to  be
f  limited  efﬁcacy  and  every  effort  must  be  made  to  achieve
ocal  control  during  initial  treatment.
No  consensus  has  been  reached  concerning  the  practi-
al  modalities  of  follow-up  of  ENB.  However,  all  authors
gree  on  the  importance  of  prolonged  follow-up  in  these
atients,  as  recurrences  can  occur  more  than  10  years  after
he  initial  diagnosis  [29]. In  our  series  of  eight  patients  in
reatment  failure,  50%  relapsed  after  5  years  and  two  of
hem  relapsed  after  10  years.  Follow-up  must  be  based  on
linical,  endoscopic  and  radiological  examination  [29]. MRI
[J.  Michel  et  al.
s the  preferred  examination  to  distinguish  recurrence  from
ost-treatment  tissue  changes  [29].
onclusion
NB  is  characterized  by  the  frequency  of  recurrences,  which
an  occur  many  years  after  the  diagnosis,  justifying  pro-
onged  follow-up  of  these  patients.  Five-year  and  10-year
verall  survival  rates  are  about  90%  and  60%,  respectively.
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